Double-blind clinical comparison between a gastrin-receptor antagonist, proglumide, and a histamine H2-blocker, cimetidine.
A double-blind trial was carried out in 30 patients with peptic ulcers to assess the effects of treatment with a gastrin-receptor antagonist, proglumide, compared with a histamine H2-blocker, cimetidine. Patients received either 1200 mg proglumide or 1200 mg cimetidine per day for 28 days. The results showed that both drugs significantly reduced clinical symptoms and gastric secretion. In patients treated with cimetidine there was a significant increase in blood gastrin levels and marked hypertrophy and hyperplasia of the antral mucosa was observed in almost all patients. No such changes were found in the patients treated with proglumide.
D000328:Adult; D002927:Cimetidine / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D005750:Gastric Juice / Q000378:metabolism; D005755:Gastrins / Q000097:blood; D005973:Glutamine / Q000031:analogs & derivatives*; D006146:Guanidines / Q000627:therapeutic use*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D008875:Middle Aged; D011377:Proglumide / Q000009:adverse effects / Q000627:therapeutic use*; D013276:Stomach Ulcer / Q000188:drug therapy* / Q000378:metabolism; D013997:Time Factors
D005755:Gastrins; D006146:Guanidines; D005973:Glutamine; D002927:Cimetidine; D011377:Proglumide